An interview with John Martin today.
He re-confirms "several interested parties" for clinical licensing Progenza in Japan as well as USA potential.
“The US is one of the hardest markets in the world to get a granted patent and we were pleased that the breadth of the claims is similar to Australia and Japan.
“We know that a granted US patent will open up partnering opportunities for us. Our research is reinforcing the advantages of the combination of stem cells and secretions.”
